NUEVAS MEDIDAS TERAPÉUTICAS EN DIABETES
Resumen
La diabetes no es una enfermedad innocua y su presencia se liga íntimamente a sus complicaciones específicas y a las primeras causas de mortalidad, tales como las patologías cardiovasculares.
Estos factores -la alta prevalencia de la enfermedad y la historia natural de la misma- han sido el motor primordial para que las autoridades sanitarias y la industria farmacéutica traten de encontrar medidas útiles para la prevención y el tratamiento de esta patología.
Palabras clave
Texto completo:
PDFReferencias
- American Diabetes Association. American Diabetes Association Calls for independent review of incretin therapy. ADA, Alexandria. VA. June 10, 2013.
- Andrianesis V, Doupis J. The role of Kidney in glucose homeostasis. SGLT 2 Inhibitors, a new approach in Diabetes treatment. Expert Rev. Clin. Pharmacol 2013; 6: 519-539.
- Gorboulev V, Schürmanss A, Vallon V. et al. Nat-Glucose-Cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion/ Diabetes 2012; 61: 187-196.
- Abbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int. J. Clin. Pract. 2008, 62: 1279-1284.
- Nainggolan L. Fungal Infections with new Diabetes drugs “Manageable”. Jul 03, 2013 Medscape Medical News. www.mediscape.com.
- Pollack A. A lone voice raises alarms on lucrative diabetes drugs. The New York times, May 30, 2013.
- Tucker ME. Experts Express Mixed thoughts on Canaglifozin Approval. April 18, 2013. Medscope Medical News. www.medscape.com.
- Tucker ME. Rosiglitazone restrictions should be eased, FDA panel ˃ayn. Jul 06, 2013 Mediscape Medical News. www. medscape.com.
- Vick H, Diedrich DF, Baumann K. Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs. Am J. Physiol. 1973; 224: 552-557.
- Yanina Pepino M, Tiemann CD, Patterson BW, Wice BM, Klein S. Diabetes Care published ahead of print April 30, 2013.
DOI: http://dx.doi.org/10.47196/diab.v47i3.210
Copyright (c) 2020 Sociedad Argentina de Diabetes Asociación Civil